Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer

被引:15
|
作者
Minami, Seigo [1 ,2 ]
Ihara, Shouichi [1 ]
Komuta, Kiyoshi [2 ]
机构
[1] Osaka Police Hosp, Dept Resp Med, Tenn Ku, 10-31 Kitayama Cho, Osaka, Osaka 5430035, Japan
[2] Daini Osaka Police Hosp, Dept Resp Med, Tenn Ku, 2-6-40 Karasugatsuji, Osaka 5438922, Japan
关键词
Gustave Roussy immune score; Royal Marsden Hospital prognostic score; Extensive disease; Small cell lung cancer; Neutrophil-to-lymphocyte ratio; Number of metastatic sites; Lactate dehydrogenase; Serum albumin; TO-LYMPHOCYTE RATIO; PHASE-I; PROSPECTIVE VALIDATION; LACTATE-DEHYDROGENASE;
D O I
10.14740/wjon1275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy inunune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. As the third risk factor, the RMII score and the GRIm-score adopt number of metastatic sites and neutrophil-to-lymphocyte ratio (NLR), respectively. We aimed to investigate whether these two systems are also useful for extensive disease of small cell lung cancer (ED-SCLC). Methods: We retrospectively collected 128 patients who had initiated platinum-based chemotherapy at our hospital between September 2007 and March 2018. We divided our patients into low (score 0 - 1) and high (2 - 3) score groups, and compared overall survival (OS) and progression-free survival (PFS) between them. Multivariate Cox proportional hazard analyses found prognostic factors of survival times. Results: Regarding GRIm-score, OS was significantly shorter in high score group than in low score group (median 6.1 vs. 11.4 months, P < 0.01), while no significant difference was observed in PFS (median 4.7 vs. 5.0 months, P = 0.12). Both OS (median 6.9 vs. 12.4 months, P < 0.01) and PFS (median 4.4 vs. 5.4 months, P = 0.01) were significantly shorter in high RMH score group than in low group. Multivariate analyses detected both high GRIm-score (hazard ratio (HR) 1.80, 95% confidence interval (CI) 1.20 - 2.72, P < 0.01) and high RMH score (HR 1.93, 95% CI 1.27 - 2.92, P < 0.01) as independent worse prognostic factors of OS, and then only high RMI1 score (FIR 1.53, 95% CI 1.04 - 2.25, P = 0.03) as independent worse prognostic factor of PFS. Conclusions: Both RMH score and GRIm-score are useful as inde- pendent prognostic factors of OS in ED-SCLC. However, only RMH score is an independent prognostic factor of PFS.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 50 条
  • [31] Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients
    Uso, Marta
    Jantus-Lewintre, Eloisa
    Calabuig-Farinas, Silvia
    Blasco, Ana
    Garcia del Olmo, Eva
    Guijarro, Ricardo
    Martorell, Miguel
    Camps, Carlos
    Sirera, Rafael
    ONCOIMMUNOLOGY, 2017, 6 (01):
  • [32] Prognostic significance of Naples prognostic score in non-small-cell lung cancer patients with brain metastases
    Xuan, Junmei
    Peng, Jianghua
    Wang, Shuai
    Cai, Yaojie
    FUTURE ONCOLOGY, 2022, 18 (13) : 1545 - 1555
  • [33] PROGNOSTIC IMPLICATIONS OF THE MODIFIED GLASGOW PROGNOSTIC SCORE IN EARLY STAGE NON-SMALL CELL LUNG CANCER
    MacKenzie, A. M.
    Johnson, E.
    Tsim, S.
    Blyth, K. G.
    THORAX, 2014, 69 : A108 - A109
  • [34] Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer
    Jiang, Ai-Gui
    Chen, Hong-Lin
    Lu, Hui-Yu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (03) : 563 - 568
  • [35] Prognostic Value of Naples Prognostic Score on Survival in Unresectable Small Cell Lung Cancer Patients Undergoing Chemoradiotherapy
    Wang, T.
    Li, J.
    Ji, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E28 - E28
  • [36] Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer
    Ai-Gui Jiang
    Hong-Lin Chen
    Hui-Yu Lu
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 563 - 568
  • [37] Prognostic significance of Memorial Sloan-Kettering prognostic score in small-cell lung cancer patients
    Chen, Shuangqing
    Liu, Shicheng
    Kong, Lingxin
    Ren, Dahu
    Hu, Zhonghui
    Wu, Wenbo
    Duan, Guochen
    BIOMARKERS IN MEDICINE, 2023, 17 (07) : 391 - 401
  • [38] Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis
    Xie, Yulian
    Li, Hongjun
    Hu, Yang
    MEDICINE, 2023, 102 (45) : E35962
  • [39] Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
    Valente, M. C. Alves
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Sousa, C.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [40] Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
    Garrido-Laguna, Ignacio
    Janku, Filip
    Vaklavas, Christos
    Falchook, Gerald S.
    Fu, Siqing
    Hong, David S.
    Naing, Aung
    Tsimberidou, Apostolia M.
    Wen, Sijin
    Kurzrock, Razelle
    CANCER, 2012, 118 (05) : 1422 - 1428